The 3rd Viral Vector Process Development and Manufacturing Summit

Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More

The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders from the likes of Sanofi, Kite, Ultragenyx, Sangamo, UCB, and more to focus on advancing the production of viral vectors for cell and gene therapeutics.

Time: 9:00 AM – 5:00 PM

Venue details: Hilton Boston Back Bay, 40 Dalton St, Boston, Massachusetts, 02115, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Andrew Steinsapir, Acting Chief Technology Officer, Apertura Gene Therapy, April Sena, Vice President, Technical Operations, Life Edit Therapeutics, Ashutosh Gupta, Director – Drug Substance Process Development and Manufacturing, Kiniksa Pharmaceuticals, Ishtiaq Khaliq, Gene Therapy and Molecular Biology Sciences Lead, UCB S.A., and more.